In vitro, RGC-32 promotes the differentiation of human Th17 cells, suggesting that RGC-32 signaling may enhance disease expression in SLE by promoting abnormalities in the Th17 pathway4. The gene discussed is RGCC; the disease is systemic lupus erythematosus.